JAZZ - Jazz Pharma reaffirms revenue guidance for 2020

Speaking at J.P. Morgan Annual Health Care Conference, Bruce C. Cozadd, Co-Founder, Chairman & CEO of Jazz Pharmaceuticals (JAZZ) said, the company expects to record ~$2.32 – 2.38B of revenue for 2020, unchanged from the previous guidance.With an estimated growth of ~7.3 – 10.1% YoY, it is a slowdown from ~14.3% YoY growth recorded in 2019.Neuroscience franchise contributing ~75.6% of total revenue is expected to result in ~$1.76 – 1.80B while $525 – 565M is projected from the oncology segment.Commenting on the long-term outlook, the CEO said: “We’ve stated that we expect new product sales of Sunosi®, Zepzelca™, Xywav™, JZP-458, and JZP-258 to account for nearly 50 percent of our revenues by 2022. That’s a dramatic change from our revenue mix this past year.”

For further details see:

Jazz Pharma reaffirms revenue guidance for 2020